ICOSLG and neoplasm: In both treated tumours and the spleen, NDV-ICOSL/anti-CTLA-4 treatment resulted in the highest increase in the percentages of CD8+ cells characterized by high expression of Granzyme B and ICOS (Fig. 6c–f).